Date: <u>March 16<sup>th</sup>, 2022</u>	
Your Name:Joshua Hefler	
Manuscript Title: Preclini	cal Systematic Review & Meta-Analysis of Cyclosporine for the Treatment of
Myocardial Ischemia-Reperfusio	on Injury
Manuscript number (if known)	ATM-22-618

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Time frame: Since the initial   X None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>_X</u> None	
З	Royalties or licenses	<u>X</u> None	
4	Consulting fees	<u>X</u> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	_XNone	
	manuscript writing or educational events		
6	Payment for expert testimony	_XNone	
7	Support for attending meetings and/or travel	<u>X</u> None	
8	Patents planned, issued or pending	<u>_X</u> None	
_			
9	Participation on a Data Safety Monitoring Board or	<u>X</u> None	
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Receipt of equipment,	<u>X</u> None	
	materials, drugs, medical writing, gifts or other		
13	services Other financial or non-	V Nono	
13	financial interests	<u>X</u> None	

None.

## Please place an "X" next to the following statement to indicate your agreement:

Date: <u>March 16<sup>th</sup>, 2022</u>	
Your Name:Braulio A. Ma	arfil-Garza
Manuscript Title:Precli	nical Systematic Review & Meta-Analysis of Cyclosporine for the Treatment of
Myocardial Ischemia-Reperfus	sion Injury
Manuscript number (if know	n):ATM-22-618

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Time frame: Since the initial   X None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>X</u> None	
3	Royalties or licenses	<u>X</u> None	
4	Consulting fees	<u>X</u> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	_XNone	
	manuscript writing or educational events		
6	Payment for expert testimony	_XNone	
7	Support for attending meetings and/or travel	<u>X</u> None	
8	Patents planned, issued or pending	<u>_X</u> None	
_			
9	Participation on a Data Safety Monitoring Board or	<u>X</u> None	
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	_XNone	
12	Receipt of equipment,	<u>X</u> None	
	materials, drugs, medical writing, gifts or other		
13	services Other financial or non-	V Nono	
13	financial interests	<u>X</u> None	

None.

## Please place an "X" next to the following statement to indicate your agreement:

Date: March 16 <sup>th</sup> , 2022	
Your Name: Sandra Ca	ampbell
Manuscript Title:Pr	eclinical Systematic Review & Meta-Analysis of Cyclosporine for the Treatment of
Myocardial Ischemia-Repe	rfusion Injury
Manuscript number (if kn	own):ATM-22-618

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Time frame: Since the initial   X None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>X</u> None	
3	Royalties or licenses	<u>_X</u> None	
4	Consulting fees	<u>X</u> None	

5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
0	testimony		
7	Support for attending	X None	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	<u>X</u> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<u>_X</u> None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	<u>X</u> None	
	materials, drugs, medical		
	writing, gifts or other		
12	services		
13	Other financial or non-	<u>X</u> None	
	financial interests		

None.

# Please place an "X" next to the following statement to indicate your agreement:

Date: <u>March 16<sup>th</sup>, 2022</u>			
Your Name:Darren H. Freed			
Manuscript Title: Preclinic	al Systematic Review & Meta-Analysis of Cyclosporine for the Treatment of		
Myocardial Ischemia-Reperfusion Injury			
Manuscript number (if known):	ATM-22-618		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Time frame: Since the initial   X None	planning of the Work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>X</u> None	
3	Royalties or licenses	<u>X</u> None	
4	Consulting fees	<u>X</u> None	

5	Payment or honoraria for	_XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
0	testimony		
7	Support for attending	X None	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	<u>X</u> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	<u>_X</u> None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	<u>X</u> None	
	materials, drugs, medical		
	writing, gifts or other		
12	services		
13	Other financial or non-	<u>X</u> None	
	financial interests		

None.

# Please place an "X" next to the following statement to indicate your agreement:

Date: March 16 <sup>th</sup> , 2022					
Your Name:A.M. James Shap	piro				
Manuscript Title:Preclinic	al Systematic Review & Meta-Analysis of Cyclosporine for the Treatment of				
Myocardial Ischemia-Reperfusion Injury					
Manuscript number (if known): _	ATM-22-618				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Time frame: Since the initial   X None	planning of the work		
	Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>X</u> None			
3	Royalties or licenses	<u>X</u> None			
4	Consulting fees	<u>X</u> None			

5	lectures, presentations, speakers bureaus,	_XNone	
	manuscript writing or educational events		
6		Y None	
6	6 Payment for expert testimony	<u>X</u> None	
	testimony		
7	Support for attending	X None	
'	meetings and/or travel		
8	Patents planned, issued or	<u>    X    </u> None	
	pending		
9	Participation on a Data Safety Monitoring Board or	<u>X</u> None	
10	Advisory Board		
10	Leadership or fiduciary role	<u>X</u> None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11		X None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	<u>X</u> None	
	services		
13	Other financial or non- financial interests	<u>_X</u> None	

None.

# Please place an "X" next to the following statement to indicate your agreement: